Intercept Pharmaceuticals Long Term Debt

Intercept Pharmaceuticals (ICPT) currently reports a long-term debt of $220M as of September 2023. That compares with $220M in the prior-year period — up 0.4% year over year. Use the charts on this page to explore Intercept Pharmaceuticals's long-term debt history and peer comparisons.

Intercept Pharmaceuticals's long-term debt increased from $220M to $220M — a 0.4% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Intercept Pharmaceuticals reported $220M in long-term debt as of September 2023. That compares with $220M in the prior-year period — up 0.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $220M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Intercept Pharmaceuticals, and consider following ICPT for alerts when major investors trade the stock.

Intercept Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $220M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ICPT with unrelated industries.